{"filing":{"accession_number":"0001104659-26-071862","cik":"0001818382","ticker":"HUMAW","company_name":"Humacyte, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"tm2617355d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926071862/tm2617355d1_8k.htm"},"events":[{"id":5870,"run_id":5149,"accession_number":"0001104659-26-071862","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Humacyte held its Annual Meeting on June 9, 2026, where stockholders voted on and approved five proposals: election of three Class II directors, advisory approval of named executive officer compensation, frequency of future advisory votes on compensation, ratification of PwC as independent auditor, and approval of an amendment to increase authorized common shares from 350 million to 550 million.","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-09","form":"8-K","submitted_at":null,"items":[{"id":5567,"accession_number":"0001104659-26-071862","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure describes a stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 350 million to 550 million. While this is a material corporate action requiring shareholder approval, it is primarily a routine capitalization adjustment rather than a specific event type in the taxonomy (e.g., not an earnings release, executive change, M\u0026A, restatement, or other defined material event). The increase in authorized shares is material to investors as it affects dilution potential and capital structure, but the filing centers on a procedural amendment rather than a discrete business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:32:36.204849+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5568,"accession_number":"0001104659-26-071862","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Humacyte's Annual Meeting held on June 9, 2026, where stockholders voted on five proposals: election of three Class II directors, advisory approval of named executive officer compensation, frequency of future advisory votes on compensation, ratification of PwC as independent auditor, and approval of an amendment to increase authorized common shares from 350 million to 550 million. All proposals passed. This is a classic shareholder vote results disclosure material to investors' understanding of governance and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:32:36.204849+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5567,"accession_number":"0001104659-26-071862","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure describes a stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 350 million to 550 million. While this is a material corporate action requiring shareholder approval, it is primarily a routine capitalization adjustment rather than a specific event type in the taxonomy (e.g., not an earnings release, executive change, M\u0026A, restatement, or other defined material event). The increase in authorized shares is material to investors as it affects dilution potential and capital structure, but the filing centers on a procedural amendment rather than a discrete business event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:32:36.204849+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-09"},{"id":5568,"accession_number":"0001104659-26-071862","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of Humacyte's Annual Meeting held on June 9, 2026, where stockholders voted on five proposals: election of three Class II directors, advisory approval of named executive officer compensation, frequency of future advisory votes on compensation, ratification of PwC as independent auditor, and approval of an amendment to increase authorized common shares from 350 million to 550 million. All proposals passed. This is a classic shareholder vote results disclosure material to investors' understanding of governance and capital structure changes.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:32:36.204849+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-09"}]}